We are live on ! Find out more
SAGE

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

248 hedge funds and large institutions have $4.65B invested in Sage Therapeutics in 2020 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 74 increasing their positions, 85 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 33

43% more capital invested

Capital invested by funds: $3.26B → $4.65B (+$1.39B)

18% more call options, than puts

Call options by funds: $54.8M | Put options by funds: $46.6M

8% more funds holding

Funds holding: 230248 (+18)

0.12% more ownership

Funds ownership: 103.25%103.37% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

13% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 85

Holders
248
Holders Change
+18
Holders Change %
+7.83%
% of All Funds
4.39%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
51
Increased
74
Reduced
85
Closed
33
Calls
$54.8M
Puts
$46.6M
Net Calls
+$8.17M
Net Calls Change
-$24.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$675M +$778K +10,559 +0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$398M +$5.8M +78,675 +2%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$371M +$298M +4,045,121 +1,696%
BlackRock
4
BlackRock
New York
$252M -$6.16M -83,586 -3%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$204M -$14.9M -201,692 -8%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$190M -$19.8M -268,179 -11%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$171M +$26.5M +359,110 +22%
Artisan Partners
8
Artisan Partners
Wisconsin
$138M +$11.8M +159,484 +11%
BG
9
Bellevue Group
Switzerland
$136M -$884K -12,000 -0.8%
State Street
10
State Street
Massachusetts
$133M +$3.28M +44,480 +3%
JP Morgan Chase
11
JP Morgan Chase
New York
$130M -$2.21M -30,001 -2%
Invesco
12
Invesco
Georgia
$128M -$759K -10,293 -0.7%
BC
13
Boxer Capital
California
$94.6M
FCM
14
Farallon Capital Management
California
$90.8M
Victory Capital Management
15
Victory Capital Management
Texas
$63.5M -$25.3M -342,840 -32%
MWNA
16
Marshall Wace North America
New York
$62.4M +$22.1M +299,169 +71%
Deutsche Bank
17
Deutsche Bank
Germany
$61.9M +$32.5M +441,228 +161%
Goldman Sachs
18
Goldman Sachs
New York
$56.6M +$8.96M +121,525 +23%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$55.2M +$2.7M +36,687 +6%
PAI
20
Palo Alto Investors
California
$51.1M
Jennison Associates
21
Jennison Associates
New York
$48.8M +$9.26M +125,603 +29%
Norges Bank
22
Norges Bank
Norway
$44M -$4.16M -56,500 -10%
Citadel Advisors
23
Citadel Advisors
Florida
$43.2M -$68.2M -925,619 -65%
GPP
24
Great Point Partners
Connecticut
$39.3M -$111M -1,512,271 -77%
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$38.2M -$36.9M -500,000 -53%

SAGE Hedge Fund Activity: Q4 2020 in Review

248 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2020, worth a combined $4.65B — up 43% from $3.26B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new SAGE positions and 33 closed out — a net gain of 18 holders — while 74 added to existing stakes and 85 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $298M. The largest seller was Great Point Partners, cutting an estimated $111M.

  • 248 institutional investors held Sage Therapeutics (SAGE) as of Q4 2020, up from 230 in Q3 2020.
  • Funds reported $4.65B of Sage Therapeutics stock for Q4 2020, up 43% quarter-over-quarter.
  • 51 funds opened new Sage Therapeutics positions in Q4 2020 and 33 closed out, a net change of +18 holders.
  • The largest Sage Therapeutics buyer in Q4 2020 was Wellington Management Group, an estimated $298M added.
  • The largest Sage Therapeutics seller in Q4 2020 was Great Point Partners, an estimated $111M sold.

Based on aggregated 13F filings for Q4 2020.